ISSN: 0340-7004

Journal Guideline

Cancer Immunology, Immunotherapy Q1 Unclaimed

Springer Science and Business Media Deutschland GmbH Germany

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).CIMT: http://www.cimt.eu/homeCCIC: http://www.immunotherapycancer.ca/JACI: http://www.jaci.jp/eng/index.htmlNIBIT: http://www.nibit.org/index.phpSEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK CITIM: http://www.canceritim.org 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again It has an SJR impact factor of 1,663.

Cancer Immunology, Immunotherapy focuses its scope in these topics and keywords: cells, cell, t, cancer, immune, human, cd, responses, tumor, suppressor, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Immunology (Q1) Immunology and Allergy (Q1) Immunology and Allergy (Q1) Medicine (miscellaneous) (Q1) Oncology (Q1)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,663

SJR Impact factor

130

H Index

283

Total Docs (Last Year)

700

Total Docs (3 years)

12270

Total Refs

4280

Total Cites (3 years)

682

Citable Docs (3 years)

5.8

Cites/Doc (2 years)

43.36

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Annual Review of Public Health Q1
Annual Review of Pathology: Mechanisms of Disease Q1
The Lancet Global Health Q1
Annual Review of Clinical Psychology Q1
JAMA - Journal of the American Medical Association Q1

Compare this journals

Aims and Scope

Best articles by citations

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-a2a and interleukin-2

The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies

Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine

Immunological inhibition of carcinogenesis

Structure and function of ETAA16: a novel cell surface antigen in Ewing's tumours

Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer

Modulation of costimulation to enhance tumor immunity

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?

The effect of ranitidine on cellular immunity in patients with multiple myeloma

The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2

Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells

Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis

SHOW MORE ARTICLES

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

Production of a human monoclonal antibody recognising a determinant on mouse IgG2b from a patient receiving mouse monoclonal antibody for diagnostic imaging

Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: Implication of monocyte-derived neutrophil-activating factors

Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation a

Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro

Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-a-treated chronic myelogenous leukaemia patients

Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons

Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association

Two-dimensional gel analysis of polypeptides from normal, preneoplastic and neoplastic mouse mammary tissues

The effects of ?GalCer-induced TCRV?24'V?11+ natural killer T cells on NK cell cytotoxicity in umbilical cord blood

Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide

Tumour escape: antitumour effectors too much of a good thing?